Intravenous everolimus nanoparticle Sapu003 outperforms oral dosing in glioblastoma mice and enters a Phase 1b trial
A cholesterol-PEG nanoparticle makes the mTOR inhibitor everolimus injectable. In mice it beat oral dosing, and a Phase 1b cancer trial is now underway.
Summary
Everolimus, a rapamycin-class mTOR inhibitor, dissolves poorly in water and is absorbed only about 15-20% when swallowed, so no intravenous version has existed. Researchers screened a library of PEG-based polymers and chose mPEG-cholesterol, which wraps the drug in tiny particles about 13 nm across. A related fatty-acid polymer caused severe tail necrosis in mice and was dropped. The cholesterol version was well tolerated. Three GMP batches were made at 12 g scale and stayed stable refrigerated for six months. In mice with human glioblastoma tumors, weekly IV dosing at 30 mg/kg gave far smaller tumors at day 28 than oral everolimus. This is a formulation and mouse efficacy study, not human efficacy data. A Phase 1b trial with exemestane is ongoing (NCT07369505).
Detailed Summary
Everolimus and its parent compound sirolimus (rapamycin) inhibit mTOR, a central growth and aging pathway. Everolimus is approved in oncology and transplantation, but only as a pill, with about 15-20% oral bioavailability. Its extreme hydrophobicity has blocked an intravenous form. A reliable injectable rapalog could allow precise dosing and open new uses, which is why the formulation work matters.
The authors screened a library of mPEG block copolymers for the ability to encapsulate everolimus in self-assembling nanoparticles, which they call Deciparticles. Nine polymers formed stable particles. Two finalists, mPEG-CONH-C18 and mPEG-cholesterol, both gave particles of about 12 nm that were stable for 24 hours. However, in tumor-bearing mice the C18 formulation caused severe tail necrosis at the injection site and was eliminated. The authors did not investigate the cause. The cholesterol version showed no injection-site toxicity.
Formulation design mapped 49 conditions varying concentration, drug-to-polymer ratio, ethanol and lactose. Particle size ranged from 7.8 to 288 nm. Drug-to-polymer ratio was the only significant main effect (F = 6.42, p = 0.0155). A ratio of 1:5 or higher gave compact particles of about 12-13 nm, with API about 16.7% of mass. The platform also accommodated sirolimus, temsirolimus, ridaforolimus, umirolimus, tacrolimus, cyclosporine and exenatide. Pimecrolimus gave oversized particles. Liraglutide, semaglutide and dulaglutide did not form stable particles.
In plasma from mouse, rat, dog, monkey and human, everolimus binding exceeded 99.6-99.9%, with free drug below the 1 nM quantitation limit. Three cGMP batches of 12 g each gave bulk recovery above 96% and fill accuracy above 98%. Release testing showed assay 94.5-98.4%, reconstituted particle size 13.1-13.9 nm, and residual ethanol under 200 ppm, far below the 5000 ppm limit. At 2-8 C, purity held for at least six months. At 25 C/60% RH assay fell about 5%, and at 30 C/65% RH it fell over 30%, so refrigeration is required. In-use stability was driven mainly by in-use time and temperature.
In the efficacy test, mice with U-87MG glioblastoma xenografts received 30 mg/kg IV Sapu003 or oral everolimus. Saline controls reached 2380 mm3 by day 17. All treated groups were strongly suppressed on day 17 (p < 0.001), with oral and IV roughly comparable at that point. By day 28, weekly IV Sapu003 tumors measured 845 mm3 versus about 2370-2650 mm3 for all oral regimens (p < 0.05). Authors report tumor growth inhibition of 97-98% and no phlebitis with repeated tail-vein dosing.
This is mainly a pharmaceutics and manufacturing paper with one mouse efficacy model. It shows mechanism-linked antitumor activity and a workable formulation, but no human efficacy, safety or pharmacokinetic data. Lifespan and aging endpoints were not studied. Human results will come from the ongoing Phase 1b trial in mTOR-sensitive solid tumors.
Key Findings
- mPEG-cholesterol formed about 12-13 nm everolimus nanoparticles; ratio of 1:5 or higher gave robust small particles (ratio effect F=6.42, p=0.0155; 49 formulation runs)
- mPEG-CONH-C18 formulation caused severe tail necrosis in mice and was discarded; the cholesterol version showed no injection-site toxicity and no phlebitis with repeated dosing
- Three 12 g cGMP batches: bulk recovery above 96%, fill accuracy above 98%, assay 94.5-98.4%, particle size 13.1-13.9 nm, residual ethanol under 200 ppm (limit 5000 ppm)
- Stable at 2-8 C for at least six months; at 25 C/60% RH assay fell about 5%, and at 30 C/65% RH it fell over 30%
- Plasma protein binding exceeded 99.6-99.9% across mouse, rat, dog, monkey and human plasma, with free drug below 1 nM
- In U-87MG glioblastoma xenografts, day-28 tumor volume was 845 mm3 for weekly IV Sapu003 versus about 2370-2650 mm3 for all oral everolimus regimens (p<0.05); reported tumor growth inhibition 97-98%
- Platform also formed particles with sirolimus, tacrolimus, cyclosporine and exenatide, but not liraglutide, semaglutide or dulaglutide
Methodology
Preclinical formulation and manufacturing study. Polymer screening used dynamic light scattering, and a 49-run design with ANOVA tested concentration, ratio, ethanol and lactose. Release, stability and ethanol testing (HS-GC/FID) covered three cGMP batches, plus a 444-run split-plot in-use stability model. Efficacy used randomized U-87MG xenograft mice in seven groups at 30 mg/kg, IV versus oral; saline controls were euthanized after day 17. Group sizes were not stated in the supplied text.
Study Limitations
Efficacy rests on a single mouse xenograft model, and the cause of C18-related necrosis was not investigated. Human safety, pharmacokinetics and efficacy remain unshown. The authors are affiliated with the company developing Sapu003 (a likely conflict of interest), and the text supplied was truncated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
